Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis

Part of paid clinical trials in Charlottesville, Virginia.

Sponsor
University of Virginia
Study ID
NCT06853145
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Idiopathic Pulmonary Fibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Hyperpolarized Xe129 — DRUG
    Hyperpolarized Xe129-MRI: Patients will undergo hyperpolarized Xe129-MRI at the University of Virginia Radiology Imaging Core (Charlottesville, VA, USA). The entire procedure visit takes approximately 3 hours based on our team's experience.

Study Details

Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.

Key Dates

Start date
May 1, 2025
Status verified
Apr 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
6 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Other: IPF subjects
    IPF subjects will undergo Xe-129 MRI

Primary Outcome Measure

Measuring the ventilation effect of HXe129 MRI for IPF subjects [ Time Frame: Up to 24 hours post MR Imaging ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Snyder Building 480 Ray C. Hunt DriveCharlottesvilleVirginia22908
Roselove Asare, MA
[email protected]
434-243-6074
Carol Bampoe, BS
[email protected]
4342439634
Yun M Shim, MD (SUB_INVESTIGATOR)
John Kim, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Charlottesville, VA

By research site
Snyder Building 480 Ray C. Hunt Drive· Charlottesville, VA

Related Studies